Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

NCT05438732 · View on ClinicalTrials.gov ↗

Study Summary

The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

Interventions

  • DEVICE smaller incision, new generation implantable miniature telescope (SING-IMT)

Study Locations (10)

California

  • Loma Linda University — Loma Linda
  • Eye Physicians of Long Beach — Long Beach

Florida

  • Sarasota Retina Institute — Sarasota

Massachusetts

  • Tallman Eye Associates — Lawrence

Michigan

  • Oakland Ophthalmic Surgery — Birmingham

Nebraska

  • Vance Thompson Vision — Omaha

New Jersey

  • Atlantic Eye Physicians — Eatontown

North Carolina

  • Western Carolina Retinal Associates — Asheville

Ohio

  • Cleveland Clinic | Cole Eye Institute — Cleveland

Trial Details

FieldValue
Enrollment Target 125 participants
Start Date 2022-06-16
Est. Completion 2025-12
Phase NA

Sponsor

VisionCare

1 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05438732

The ClinicalTrials.gov registry entry for NCT05438732 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 125 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VisionCare, which has 1 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Age-Related Macular Degeneration appearing as the primary indexed condition, and to 1 intervention — of which smaller incision, new generation implantable miniature telescope (SING-IMT) is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT05438732 reports 10 study locations spanning 9 distinct geographic areas — top geographies include California, Florida, Massachusetts. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT05438732 about?

NCT05438732 is a clinical study titled "Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD". The objective of this study is to determine the safety and effectiveness of the smaller incision, new generation (SING), implantable miniature telescope (IMT) in patients with moderate-severe central vision loss due to late-stage age-related macular degeneration (AMD).

What is the current status of trial NCT05438732?

This trial is currently recruiting. It is a NA study. The enrollment target is 125 participants. The study started on 2022-06-16. Estimated completion is 2025-12.

What conditions does trial NCT05438732 study?

This clinical trial studies the following conditions: Age-Related Macular Degeneration, Geographic Atrophy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT05438732?

The interventions under investigation include: smaller incision, new generation implantable miniature telescope (SING-IMT) (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT05438732?

This trial is sponsored by VisionCare, which has 1 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT05438732 being conducted?

This trial has 10 study locations across California, Florida, Massachusetts, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial